Hasil Pencarian  ::  Simpan CSV :: Kembali

"Graves disease is an autoimmune disorder which affect thyroid gland. Graves disease is the most common cause of hyperthyroidism and thyrotoxicosis. Understanding of disease pathophysiology, diagnostic and treatment strategies, and prevention of disease relapse are important for all clinicians especially internal medicine specialist to give optimal and comprehensive management for Graves disease patients. This article highlights clinical points to treat Graves disease patients from reviews and latest guidelines from American Thyroid Association (ATA), European Thyroid Association (ETA), and Japan Thyroid Association/ Japan Endocrine Society."

"Background: thyroid dysfunction is more likely to occur in diabetes mellitus patients than general population. Until now, no study has been done to find prevalence of hypothyroidism and hyperthyroidism in Indonesian diabetics. This study aimed to find the proportion and characteristics of thyroid dysfunction in Indonesian type 2 diabetes mellitus patients. Methods: a cross-sectional study was conducted in Endocrine and Diabetes Polyclinic, Department of Internal Medicine, Cipto Mangunkusumo Hospital from July to September 2015. This study include type 2 diabetes mellitus patients, age ≥ 18 year-old, willing to undergo thyroid laboratory testing. In this study, hypothyroidism defined as TSH more than 4.0 mIU/L, while hyperthyroidism is defined as TSH less than 0.4 mIU/L with eCLIA. Results: from 364 subjects who were recruited from Endocrine and Diabetes Polyclinic, Cipto Mangunkusumo Hospital, 303 subjects underwent this study until analysis. Two hundred and three (273) subjects (90.1%) were euthyroid, 7 subjects (2.31%) were hyperthyroid, and 23 subjects (7.59%) were hypothyroid. Majority of the patients had subclinical hypothyroidism (56.5% based on Zulewski and Billewicz Score and 65.2% based on fT4 laboratory result), while 42.9% and 71.4% subjects had clinical hyperthyroidism based on clinical appearance and fT4 laboratory result respectively. Conclusion: proportion of hypothyroidism was 7.59% and hyperthyroidism was 2.31%, while the proportion of total thyroid dysfunction was 9.9% among diabetics. It is suggested that screening for thyroid dyscfunction can be done in high risk condition as a part of comprehensive management in type 2 diabetes mellitus patients."

"Latar Belakang: Tujuan studi ini adalah membandingkan terapi antara siklofosfamid dan mikofenolat mofetil pada remisi nefritis lupus melalui sebuah laporan kasus berbasis bukti (evidence-based case report) yang diperoleh dari telaah sistematis dan meta-analisis.Metode: Metode yang digunakan pada studi ini adalah laporan kasus berbasis bukti menggunakan telaah sistematis dan meta-analisis. Pertanyaan klinis adalah manakah terapi imunosupresan yang memberikan hasil lebih baik pada remisi nefritis lupus; siklofosfamid atau mikofenolat mofetil? Untuk menjawab pertanyaan tersebut, kami melakukan pencarian dari situs PubMed dengan kata kunci ?lupus nephritis AND mycophenolate mofetil AND cyclophosphamide? dengan batasan telaah sistematis dan/atau meta-analisis, bahasa Inggris, dan hanya melakukan perbandingan secara spesifik terhadap kedua obat.Hasil: Dari pencarian awal, kami memperoleh 11 artikel telaah sistematis dan/atau meta-analisis terkait terapi nefritis lupus. Satu artikel dieksklusi karena berbahasa Yahudi, empat artikel lain dieksklusi karena tidak spesifik melakukan perbandingan terhadap mikofenolat mofetil dan siklofosfamid sehingga diperoleh enam studi yang ikut serta dalam telaah kritis dan diskusi laporan kasus kami.Kesimpulan: Berdasarkan bukti-bukti ilmiah yang diperoleh, mikofenolat mofetil memberikan efektivitas yang sama (non-inferior) dengan siklofosfamid dalam mencapai remisi pada nefritis lupus, tetapi memiliki tingkat keamanan yang lebih baik daripada siklofosfamid. Pasien pada kasus mendapatkan mikofenolat mofetil dan telah menunjukkan perbaikan secara klinis ke arah remisi pada evaluasi pasca-rawat inap

---

Background: The aim of this case study is to compare the effectiveness between cyclophosphamide and mycophenolate mofetil to achieve remission of lupus nephritis in an evidence-based case report from meta-analyses.

Methods: Method in this case study is evidence-based case report using meta-analyses. Clinical question used in this paper is; which immunosuppressant gives better result in achieving remission in lupus nephritis patient: cyclophosphamide or mycophenolate mofetil? To answer this question, we search the evidence from PubMed with the keywords: ?lupus nephritis AND mycophenolate mofetil AND cyclophosphamide? with inclusion criteria of meta-analysis, written in English, and focused comparing cyclophosphamide and mycophenolate mofetil.

Results: From the searching method, we found 11 articles which is relevant. One has been excluded since it written in Hebrew, 4 articles excluded since are not focus answering the clinical question. At the end, 6 studies were included to the critical appraisal step.

Conclusion: Based on the evidences, mycophenolate mofetil is non-inferior to cyclophosphamide in achieving remission in lupus nephritis patients, but with the better safety profile. Patient in our case study get mycophenolate mofetil and shows better clinical condition towards remission as she are evaluated in the outpatient clinic."